Digital Marketing for Life Sciences: Stage Before Channel
Digital Marketing for Life Sciences: Stage Before Channel
Digital marketing for life sciences companies fails because founders pick channels before understanding their commercial stage. FDA clearance is the starting line, not the finish line. And most life sciences digital marketing strategies don't account for what happens between the starting line and commercial traction.
Watch the 2024 Medtech Growth Marketing Strategies episode on YouTube
Key Takeaways
- Digital marketing for life sciences must map to buyer stage, not channel familiarity or budget size.
- LinkedIn's primary job at pre-traction stage is category narrative, not inbound lead generation.
- Direct digital outreach via LinkedIn at pre-traction stage builds IDN pipeline faster than LinkedIn Sponsored Content to procurement committees.
- Running LinkedIn Sponsored Content to IDN procurement committees is channel-stage mismatch, not a budget problem.
- Post-traction life sciences digital marketing strategy shifts to paid search for brand defense and content for inbound qualification.
Why Life Sciences Digital Marketing Is Built on a Channel-First Mistake
Every agency pitch in medtech starts with channels. You need LinkedIn Sponsored Content. You need retargeting. You need an email nurture for your physician list.
Founders buy it because channels feel concrete. You can point to a LinkedIn campaign manager. You can show impressions.
But channels are outputs. Stage is the input.
I've watched this play out in 370+ episodes of The State of MedTech. A surgical robotics company spends $40K on LinkedIn campaigns targeting hospital executives before their clinical data is published. An orthopedic implant startup builds an email nurture sequence to GPO procurement committees eight months before its commercial launch.
The campaigns run. The metrics look fine. And nothing closes.
This is the core failure of life sciences digital marketing strategy: channel familiarity masquerading as strategy. Medtech founders pick the channels they've seen work somewhere else, in a different market, at a different commercial stage, and try to run the same plays.
And the market doesn't respond. So they spend more. Or they hire a bigger agency. And the cycle repeats.
The diagnosis is almost always the same. The channel isn't wrong. The timing is.
I covered this on an episode on 2024 medtech growth marketing strategies. The point on ICP channel behavior stood out:
"The CEO, CTO, the VPs of X, they're on LinkedIn because that's where their peers are. You really have to know your channels, know your target market, and what they're using those channels for."
That last line is the one that most life sciences digital marketing strategies miss. It's about what buyers are using the channel for, and whether your message matches their intent at this exact stage.
How Pre-Traction Digital Marketing for Life Sciences Companies Should Be Structured
Before you have commercial traction in life sciences, you have a category problem, not a marketing problem.
Buyers don't know your product exists. More important: they don't know they should care about the problem your product solves. The job of digital marketing at pre-traction stage is to engineer enough market awareness that your first commercial conversations aren't starting from zero.
That changes everything about channel selection.
LinkedIn is the right channel at pre-traction, but the job is building the category narrative. Surgeon content. Founder thought leadership. Case discussion posts. The goal is to make the problem visible to the clinical champions who will later pull the device through procurement.
Video and podcast are the pre-traction channels for clinical champion development. When I was a clinical rep at Mazor Robotics, the surgeons who championed robotic surgery weren't convinced by a PPC campaign.
They were convinced by peer conversations, clinical data in accessible formats, and early-adopter surgeons they respected making the case on video.
Direct outreach handles surgeon engagement. Targeted, high-personalization outreach to the ten surgeons in a geography whose adoption patterns will define your market position.
Tony Recupero, President of SI-BONE, demonstrated what this looks like in practice. I interviewed him on an episode about lessons from US Surgical, Kyphon, and SI-BONE. He described a 30-minutes-a-day digital outreach discipline that produced results worth paying attention to:
"In 60 days, I was able to put 35 deals in the pipeline of a variety of different hospitals, big hospitals such as University of Kansas, UCSF, or Cleveland Clinic, using LinkedIn and a few other digital channels."
Thirty minutes a day. Sixty days. Thirty-five deals across tier-one academic medical centers.
That's targeted digital outreach mapped to where buyers respond.
How Life Sciences Digital Marketing Strategy Changes Post-Traction
Once you have clinical traction, commercial validation, and named adopters, the job of digital marketing changes entirely.
Pre-traction, you were engineering the category. Post-traction, you're defending the brand and accelerating inbound qualification.
Paid search becomes a legitimate channel post-traction because now there are buyers with explicit intent. Surgeons who've heard about your device. Administrators who've seen it at a conference.
IDN decision-makers whose clinical champion has already made the internal case. These buyers are searching. Paid search captures them before a competitor does.
Content shifts from category narrative to clinical evidence delivery. Post-traction, the content job is to make the clinical case accessible to the non-surgeon stakeholders who influence procurement. White papers, clinical study summaries, and economic outcome data formatted for a VP of Supply Chain are inbound qualification tools, not category engineering.
And LinkedIn Sponsored Content starts to make sense post-traction, but only for a specific audience: executives at institutions where your device is already in use and where you're trying to expand utilization.
On an episode about using LinkedIn Ads to attract early adopter surgeons and discover KOLs, the distinction between digital opinion leaders and traditional KOLs makes the channel logic clear:
"A digital opinion leader is someone who is essentially influencing the masses digitally. Not every KOL is a DOL and not every DOL is a KOL. Because of their reach, they can persuade people at scale through the digital channels."
At pre-traction, you're developing your DOLs. Post-traction, you're activating them. Same channel. Completely different job.
Why LinkedIn Ads to IDN Procurement Committees Burn Budget Before Traction
This is the specific failure I see most consistently in life sciences digital marketing strategies: running LinkedIn Sponsored Content to IDN procurement committees at pre-traction stage.
IDN procurement committees evaluate decisions that clinical champions have already made internally. LinkedIn ads can reach them. But the intent to discover new technology through a social media feed isn't there, the internal narrative isn't in place, and the ad spend generates impressions with no commercial downstream.
Targeting procurement committees on LinkedIn before your clinical champions have created internal pull is the channel-stage mismatch in its clearest form. It's like buying Google Ads for a capital equipment category that doesn't exist yet in the buyer's search behavior.
I covered the opportunity this misses on an episode on the state of sales in biotech and medtech. The context was LinkedIn content creation, but the structural point holds:
"Of the 750 million users globally, only 3 million of them make content, so about one percent of all of LinkedIn's users makes content. You don't even have to be the best; you just have to be the one who shows up and does it on a consistent basis."
Life sciences digital marketing rewards out-positioning. One percent of LinkedIn users create content in any category. In medtech, the number is smaller. A clinical champion who creates consistent, authoritative content about a procedure you enable is worth more than ten LinkedIn ad campaigns to procurement committees.
What This Means for Medtech Founders
In my experience working with medtech founders, the single most common digital marketing mistake is building a strategy around channel capabilities instead of commercial stage.
The right question is: what job does marketing need to do at this exact stage of commercialization? Then you pick channels that do that job.
Before traction: LinkedIn and video for category narrative, direct digital outreach for clinical champion development, healthcare content marketing that makes the clinical case accessible to early adopters. Build pull. Impressions are a lagging indicator of the wrong strategy.
Post-traction: paid search for brand defense, content for inbound qualification, LinkedIn advertising for account expansion within your existing clinical champion network.
The medtech companies that engineer their markets successfully don't treat digital marketing as a growth channel. They treat it as a market architecture tool.
Channels are selected based on the job to be done at each commercial stage, not based on what's familiar or what an agency's dashboard makes easy to measure.
That's the distinction between a life sciences marketing agency vs market engineering approach. Agencies manage channels. Market engineers design the commercial architecture first, then select the channels that serve it.
For more on why the pharma playbook fails in medtech, see why the life sciences marketing playbook burns medtech commercial traction.
And they do it in sequence.
Frequently Asked Questions
What Is Digital Marketing for Life Sciences Companies?
Digital marketing for life sciences uses digital channels (LinkedIn, content, paid search, email, video) to build market awareness and develop clinical champions for medical devices and diagnostics. Unlike B2C, it must account for multi-stakeholder procurement, regulatory constraints on clinical claims, and the gap between clinical adoption and commercial traction.
Which Digital Marketing Channels Work Best for Medical Device Companies?
Channel selection depends on commercial stage. At pre-traction, LinkedIn for category narrative, video for clinical champion development, and direct digital outreach for surgeon engagement produce the strongest results.
Post-traction, paid search for brand defense, content for inbound qualification, and LinkedIn advertising for account expansion become the priority. No single channel works across all commercial stages.
How Is Digital Marketing for Life Sciences Different From B2C Digital Marketing?
Life sciences digital marketing involves multi-stakeholder purchase decisions, regulatory constraints on clinical claims, and markets where clinical adoption must precede commercial traction.
The surgeon who uses the device rarely approves the purchase. Procurement, finance, and a VAC committee each need different messages at different stages. A single-buyer B2C funnel doesn't translate.
When Should a Medtech Company Invest in Digital Marketing?
Medtech companies should begin digital marketing at the clinical validation phase, not after FDA clearance. The pre-traction goal is category narrative and clinical champion development.
Waiting for clearance gives competitors a head start on seeding the category with early-adopter surgeons. The medical device go-to-market strategy should include digital marketing from clinical validation forward.
Listen to the Full Conversations
- Using LinkedIn Ads to Attract Early Adopter Surgeons and Discover KOLs, The State of MedTech, September 2024
- The State of Sales in Biotech and Medtech, The State of MedTech, March 2022
- President of SI-BONE Tony Recupero Shares Lessons From US Surgical, Kyphon, and SI-BONE, The State of MedTech, October 2022
- 2024 Medtech Growth Marketing Strategies, The State of MedTech, July 2024
Subscribe wherever you listen to podcasts.
About the Author
Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry. He works with medtech founders and commercial leaders on market engineering, commercialization strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.